European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
SAN DIEGO, Jan. 18, 2023 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the European Commission (EC) granted orphan drug designation for the company’s lead therapeutic candidate, efzofitimod, for the treatment of sarcoidosis based on the opinion of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2) and is currently being investigated in a global pivotal Phase 3 study in patients with pulmonary sarcoidosis, the main form of the disease.
Related news for (LIFE)
- Top Biotech Stocks to Watch Now: Momentum, Milestones & Market Breakouts
- aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- aTyr Pharma Announces Commencement of Public Offering of Common Stock